

# INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

## MEETING MINUTES

**Meeting Date:** Wednesday, September 24, 2025  
**Time:** 11:00 am Eastern Time  
**Location:** Zoom Teleconference  
**Institution:** University of North Carolina at Chapel Hill, Chapel Hill, NC  
**Principal Investigator:** Anne Beaven, MD  
**Protocol:** March Biosciences, Inc, MB-105-201  
**NCT Number:** NCT06534060  
**Meeting Type:** Continuing Review of Protocol and Site  
**Title:** A phase 2, open-label, multicenter study of MB-105 in patients with CD5 positive (CD5+) relapsed / refractory T-cell lymphoma (r/r TCL).

### 1. Call to order:

The Meeting was called to order at 11:16 am Eastern Time.

### 2. Introductions and orientation:

Introductions were made and the Chair oriented members to the meeting procedures.

### 3. Declaration of quorum:

Six voting members were present, including two local members unaffiliated with the institution and the Institution's Associate Biosafety Officer. Also present were three Institutional Representatives and IBC Services staff. The Chair declared that a quorum was present

### 4. Conflict of Interest:

The Chair requested that voting members report any conflict of interest regarding this meeting. No conflicts of interest were reported.

### 5. Public posting:

The Institutional Representative confirmed that notice of the meeting was publicly posted. No public comments were received by the site or the Committee regarding this review.

### 6. Approval of previous meeting minutes:

Minutes Approved - YES: 6 NO: 0 ABSTAIN: 0

### 7. Review of proposed research:

The Chair provided an overview of the protocol and status of the study.

The Chair provided an overview of changes since the last review.

### 8. Determination for biosafety level and period of IBC oversight:

The Committee previously determined that **BSL-2 containment facilities and practices** are required for MB-105, since it consists of primary human cells modified using a recombinant retroviral vector. The Committee reaffirmed this determination.

The Committee previously determined that IBC oversight will continue for **3 months after the last subject's last dose of MB105 locally**, provided all other criteria for study closure are met. The Committee reaffirmed this determination.

### 9. Vote on the Protocol:

The Committee voted for the following determination on the Protocol:

|   |                        |
|---|------------------------|
| X | APPROVED               |
|   | CONDITIONALLY APPROVED |
|   | TABLED                 |
|   | DISAPPROVED            |

DETERMINATION VOTE - YES: 6 NO: 0 ABSTAIN: 0

## INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

### **10. Review of proposed facilities and practices:**

The Chair provided an overview of the arrangement for the facilities and practices.

#### **Point of Discussion:**

1. The Committee recommended that the Institution confirm if the practice of adding a 10% bleach solution to the sink and drain after disposal of water in a waterbath is followed, even if there were no apparent leaks of the study agent into the water in the waterbath.

### **11. Site requirements:**

The Chair reviewed training and communication requirements for maintaining IBC approval with the Institutional Representatives.

### **12. Vote on the Site:**

The Committee voted for the following determination on the Site:

|   |                        |
|---|------------------------|
| X | APPROVED               |
|   | CONDITIONALLY APPROVED |
|   | TABLED                 |
|   | DISAPPROVED            |

DETERMINATION VOTE - YES: 6

NO: 0

ABSTAIN: 0

**13. Advice to the Institution:** None.

**14. Meeting adjourned:** The meeting was adjourned at 11:21 am Eastern Time.